Liposomal Amphotericin B Dosing for Active Mucormycosis
For a 73 kg male with active mucormycosis, administer liposomal amphotericin B at 5-10 mg/kg/day starting from day 1, which translates to 365-730 mg daily (typically start at 5 mg/kg = 365 mg/day). The guideline explicitly states to avoid slow dose escalation in this medical emergency 1.
Specific Dosing Calculation
For this 73 kg patient:
- Minimum dose: 5 mg/kg × 73 kg = 365 mg daily
- Maximum dose: 10 mg/kg × 73 kg = 730 mg daily
Dosing Strategy
Start at 5 mg/kg/day (365 mg) immediately. The 2019 global mucormycosis guideline from the European Confederation of Medical Mycology strongly emphasizes that mucormycosis is a medical emergency requiring rapid action, and specifically notes to avoid slow escalation of dose 1.
When to Consider Higher Doses (>5 mg/kg/day)
The evidence does not support routine escalation beyond 5-6 mg/kg/day:
- Recent 2023 Japanese nationwide data (82 cases) found no survival benefit for doses >5 mg/kg/day versus 5 mg/kg/day (HR 0.86,95% CI 0.28-2.68, p=0.796) 2
- A 2026 systematic review concluded that routine dose escalation beyond 5-6 mg/kg/day is not supported by current evidence, with consistently higher nephrotoxicity rates at higher doses 3
- The AmBiLoad trial showed no statistical efficacy difference between 3 mg/kg/day and 10 mg/kg/day, but standard dosing was better tolerated 4
Reserve doses >5 mg/kg/day only for:
- Rapidly progressive disease with CNS involvement
- Disseminated mucormycosis
- Failure to respond to standard dosing after 5-7 days
- Individualized risk-benefit assessment in critical cases
Critical Caveats
Renal Function Considerations
If pre-existing renal compromise exists, consider isavuconazole or posaconazole as first-line instead 1. However, if liposomal amphotericin B is still chosen, start at the lower end (5 mg/kg) with intensive monitoring.
Administration Details
- Infuse over 2-6 hours 5
- Monitor renal function, electrolytes (especially potassium), and infusion-related reactions closely
- Nephrotoxicity and hypokalemia are the most common adverse effects (hypokalemia in ~40% of patients) 6
Duration of Therapy
- Continue liposomal amphotericin B for at least 14 days before considering switch to triazole therapy (posaconazole or isavuconazole) 7
- A 2026 emulated trial found that switching to triazole after 14 days was as effective as longer durations while reducing side effects 7
- Total antifungal duration typically 6-8 weeks, guided by clinical response and resolution of symptoms 8
Essential Concurrent Management
Liposomal amphotericin B alone is insufficient. The guideline strongly recommends:
- Surgical debridement with clean margins (strongly recommended) 1
- Reversal of underlying immunosuppression (critical for survival)
- Control of diabetes/hyperglycemia (persistent hyperglycemia associated with mortality) 2
Combination Therapy
Do not routinely combine with other antifungals. Recent evidence shows combination therapy (L-AmB + triazole) does not improve prognosis compared to monotherapy (HR 1.14,95% CI 0.56-2.32) 7, and guidelines do not recommend routine combination therapy 9.
Practical Algorithm
- Confirm diagnosis and assess disease extent (pulmonary, rhinocerebral, disseminated)
- Start liposomal amphotericin B 5 mg/kg/day (365 mg) immediately on day 1
- Arrange urgent surgical debridement if feasible
- Optimize underlying conditions (control diabetes, reduce immunosuppression if possible)
- Monitor closely: renal function, electrolytes, clinical response
- Continue for 14+ days, then consider switch to posaconazole or isavuconazole if responding
- Only escalate dose if inadequate response after 5-7 days AND patient can tolerate increased nephrotoxicity risk
Note: This is distinct from conventional amphotericin B deoxycholate, which has different dosing (0.7-1.0 mg/kg/day) and significantly higher toxicity 5.